[Body composition and metabolic risk in small for gestational age children treated with growth hormone].

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

Their objective is to evaluate changes in body composition produced by growth hormone (GH) treatment.

Who Took Part

The abstract describes 28 children taking part.

The age groups tagged for this paper are young children and children, both men and women.

A group of 28 SGA children without catch-up growth and undergoing treatment with GH was selected for evaluation.

Over the course of 3 years from the beginning of the treatment with GH, the children's body composition variables (bone mineral density [BMD], fat and lean body mass proportion) were evaluated annually with dual-energy X-ray absorptiometry.

How the Study Was Run

A study of correlation between metabolic and body composition variables was also made.

What Was Measured

PubMed files the paper under topics including Absorptiometry, Photon, Body Composition, Bone Density, Cardiovascular Diseases, Growth Disorders, Growth Hormone and Infant, Small for Gestational Age.

Author keywords: Birth weight, Body fat, Bone mineral content, Composición corporal, Contenido mineral óseo and Grasa corporal.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 28 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (Medicina clinica), a journal based in Spain.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.